alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT 32.1**

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of MEDTOX Scientific, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2008 as filed with the Securities and Exchange Commission (the “Report”), I, Richard J. Braun, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

 

 (1)                   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 (2)                   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

| Dated:   October 30, 2008 | By:   /s/ Richard J. Braun                |
|---------------------------|-------------------------------------------|
|                      | Richard J. Braun

Chief Executive Officer |

|   | 31 |
|--------|----|

 

----
§ 802.205 Time for filing. ( a ) A notice of appeal, other than a cross-appeal, must be filed within 30 days from the date upon which a decision or order has been filed in the Office of the Deputy Commissioner pursuant to section 19(e) of the LHWCA or in such other office as may be established in the future (see §§ 702.349 and 725.478 of this title).
( b ) If a timely notice of appeal is filed by a party, any other party may initiate a cross-appeal by filing a notice of appeal within 14 days of the date on which the first notice of appeal was filed, or within the time prescribed by paragraph (a) of this section, whichever period last expires. In the event that such other party was not properly served with the first notice of appeal, such party may initiate a cross-appeal by filing a notice of appeal within 14 days of the date that service is effected.
( c ) Failure to file within the period specified in paragraph (a) or (b) of this section (whichever is applicable) shall foreclose all rights to review by the Board with respect to the case or matter in question. Any untimely appeal will be summarily dismissed by the Board for lack of jurisdiction.
**Exhibit
      23**


**ARMANDO
                C. IBARRA****Certified
                Public Accountants A Professional
                Corporation**








Armando
                C. Ibarra, C.P.A.
            Members
                of the California Society of Certified Public AccountantsArmando
                Ibarra, Jr., C.P.A., JD








February
      15, 2007





To
      Whom It
      May Concern:


The
      firm
      of Armando C. Ibarra, Certified Public Accountant, APC consents to the inclusion
      of our report dated March 20, 2006 on audited financial statements of Frezer,
      Inc. for the year ended December 31, 2005 in any filings that are necessary
      now
      or in the future with the U.S. Securities and Exchange Commission including,
      without limitation, the Annual Report of Frezer, Inc. on Form 10-KSB for the
      year ended December 31, 2006.





Very
      Truly
      yours,


/s/
      Armando C Ibarra


Armando
      C.
      Ibarra, C.P.A.
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

DAY ELEV

 2,281.76

 2,281.55

 2,281.71

 2,282.05

 2,282.74

 2,283.16

 2,283.30

 2,283.31

 2,283.29

 2,283.34

 2,283.39

 2,283.43

 2,283.45

 2,283.51

 2,283.44

 2,283.61

 2,283.93

 2,284.27

 2,284.47

 2,284.60

 2,284.69

 2,284.75

 2,284.82

 2,284.90

 2,284.91

 2,284.88

 2,284.87

 2,284.88

 2,284.83

 2,284.83

 2,284.86

 1,257.9

 1,255.7

 1,257.4

 1,260.9

 1,268.3

 1,272.7

 1,274.2

 1,274.3

 1,274.1

 1,274.6

 1,275.2

 1,275.6

 1,275.8

 1,276.4

 1,275.7

 1,277.5

 1,280.9

 1,284.6

 1,286.7

 1,288.1

 1,289.1

 1,289.7

 1,290.5

 1,291.3

 1,291.4

 1,291.1

 1,291.0

 1,291.1

 1,290.6

 1,290.6

 1,290.9

STORAGE

-3.9

-2.2

+1.7

+3.6

+7.3

+4.5

+1.5

+0.1

-0.2

+0.5

+0.5

+0.4

+0.2

+0.6

-0.7

+1.8

+3.4

+3.6

+2.1

+1.4

+1.0

+0.6

+0.8

+0.9

+0.1

-0.3

-0.1

+0.1

-0.5

+0.0

+0.3

CHANGE

2,288

3,465

5,321

6,107

8,484

6,411

5,234

4,100

3,565

3,404

3,317

2,972

2,707

2,910

3,054

3,451

3,903

3,898

3,204

2,906

2,475

2,514

2,440

2,400

2,141

2,054

2,128

2,092

1,942

1,790

1,673

INFLOW

 4,211

 4,225

 4,145

 4,007

 4,381

 4,128

 4,227

 3,981

 3,600

 3,072

 2,951

 2,346

 2,518

 2,518

 3,384

 2,430

 2,069

 1,971

 1,995

 2,088

 1,899

 2,097

 2,004

 1,853

 2,001

 2,115

 2,093

 1,949

 2,112

 1,714

 1,435

POWER

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 3

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

SPILL

 4

 339

 327

 264

 375

 0

 198

 0

 0

 0

 0

 314

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

 0

OUTLET

 40

 15

 0

 31

 44

 34

 56

 66

 72

 63

 97

 97

 78

 69

 47

 107

 113

 88

 126

 114

 89

 92

 57

 114

 86

 101

 89

 89

 101

 76

 76

C.F.S.

 .13

 .05

 .00

 .10

 .14

 .11

 .18

 .21

 .23

 .20

 .31

 .31

 .25

 .22

 .15

 .34

 .36

 .28

 .40

 .36

 .28

 .29

 .18

 .36

 .27

 .32

 .28

 .28

 .32

 .24

 .24

INCHES

 .06

 .26

 1.53

 .02

 1.39

 .19

 .01

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

 .00

PRECIP

UNITED STATES DEPARTMENT OF THE INTERIOR

U.S. BUREAU OF RECLAMATION-CENTRAL VALLEY PROJECT-CALIFORNIA

MAY 2009 TRINITY LAKE DAILY OPERATIONS RUN DATE: June 1, 2009

IN LAKE

EVAPORATION

INCHES

C.F.S.

COMPUTED*

1000 ACRE-FEET

RELEASE - C.F.S.

TOTALS +29.1 104,350 85,519 3 1,821 2,327 7.39 3.46

ACRE-FEET +29,100 206,978 169,627 6 3,612 4,616

COMMENTS:

* COMPUTED INFLOW IS THE SUM OF CHANGE IN STORAGE, RELEASES AND EVAPORATION.

(1) EVAPORATION AND PRECIPITATION RECORDS TAKEN FROM STATION AT TRINITY RIVER HATCHERY.

SUMMARY RELEASE (ACRE-FEET)

POWER 169,627

SPILL 6

OUTLET

TOTAL

 3,612

 173,245

PRECIPITATION

THIS MONTH =

TO DATE =

 3.46

JULY 1, 2008 19.96

 1,261.8

(1) (1)
EXHIBIT 32.1

                   CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                              MARWICH II, LTD.
                    PURSUANT TO 18 U.S.D. SECTION 1350


In connection with the Quarterly Report of Marwich II, Ltd. (the "Company") on
Form 10-QSB for the period ended October 31, 2004, as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Peter Porath,
Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. SS
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that to the best of my knowledge:

     (1)  The Report fully complies with the requirements of Section 13(a) or
15(d), as applicable, of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.



/s/ Peter Porath
Peter Porath
Vice-President, Chief Executive Officer
November 15, 2004
Exhibit 10.4


 


 


 


January 21st, 2021


 


		To:	Eco Wave Power Ltd.



Derech Menachem Begin 52


Tel Aviv 


 


		From:	Mr. David Leb



Director and shareholder


 


Subject: Outstanding loans from David
Leb to Eco Wave Power Ltd.


 


This is to confirm that on December 31st,
2019 I had the following 2 outstanding loans to Eco Wave Power Ltd. (Hereinafter - “EWP”):


 


		1.	$200k loan – In accordance with the loan agreement dated June 1st, 2019 the loan must be repaid through monthly instalments
of $666 from January 2019. The remaining amount and accrued interest at the rate of 4%, must be repaid within 12 months. As of the date
of the loan agreement and 12 months from the date of this letter, I do not intend to withdraw loan amounts.



 


The loan amount as of December 31st, 2019 was
$204,667 including interest.


 


The loan amount as of December 31st, 2020 was
$212,667 including interest.


 


		2.	$800k loan - In accordance with the loan agreement dated June 1st, 2019 the credit period is 36 months and if the loan is not repaid
within the credit period, an interest rate of 4% applies. The decision whether to pay within 36 months or not lies with the company.



 


The loan amount as of December 31st, 2019 was $800,000. The
company accrued $18,667 interest in case it will not pay within the 36 months period.


 


The loan amount as of December 31st, 2020 was $800,000. The
company accrued $50,667 interest in case it will not pay within the 36 months period.


 


	Sincerely,	 
	 	 
	David Leb	 
	Director and shareholder
#### § 2543.3 Purchase price required.

If upon consideration of the application it shall be determined that the applicant is entitled to purchase the lands applied for, the applicant will be notified by registered mail that he must within 30 days from service of notice deposit the appraised price, or thereafter, and without further notice, forfeit all rights under his application.
Exhibit 21.1

Abraxis BioScience, Inc.

List of Subsidiaries

The following is a list of subsidiaries of Abraxis BioScience, Inc. as of December 31, 2006, omitting some subsidiaries which, considered in the
aggregate, would not constitute a significant subsidiary.



|                                            |  |                   
|------------------------------------------- |  | ------------------
|Name                                        |  | Where Incorporated
|                                            | 
|Pharmaceutical Partners of Canada           |  | Ontario, Canada   
|                                            | 
|WebDrugSource.com, Inc.                     |  | California        
|                                            | 
|APP International Holding Company, Inc.     |  | Delaware          
|                                            | 
|Pharmaceutical Partners of Europe B.V.      |  | Netherlands       
|                                            | 
|Pharmaceutical Partners of Europe C.V.      |  | Netherlands       
|                                            | 
|Pharmaceutical Partners of Switzerland GmbH |  | Switzerland       
|                                            | 
|South African Pharmatech (Pty) Limited      |  | South Africa      
|                                            | 
|Abraxis Bioscience Manufacturing, LLC       |  | Puerto Rico       
|                                            | 
|Chicago Bioscience, LLC                     |  | Illinois          
|                                            | 
|Transplant Research Institute               |  | California        
|                                            | 
|Resuscitation Technologies, LLC             |  | Delaware          
|                                            | 
|VivoRx Autoimmune, Inc.                     |  | California        
|                                            | 
|APP Strategic Partners I, LLC               |  | Delaware          
|                                            | 
|Jefferson XIII, LLC                         |  | Delaware          
|                                            | 
|Readyflex Solutions LLC                     |  | Delaware          
|                                            | 
|Readyflex Solutions LLC                     |  | Puerto Rico       
|                                            | 
|Abraxis Bioscience Limited                  |  | United Kingdom    
|                                            | 
|Abraxis Bioscience Australia Pty Ltd.       |  | Australia         
|                                            | 
|Drug Source Company, LLC                    |  | Delaware
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

DAY HIGH

 633

 619

 638

 643

 632

 664

 668

 605

 609

 615

 621

 594

 403

 297

 278

 280

 330

 369

 388

 420

 469

 489

 544

 602

 630

 654

 659

 649

 640

 651

 593

 573

 596

 614

 602

 637

 601

 584

 598

 602

 609

 407

 307

 274

 266

 269

 270

 329

 371

 386

 413

 465

 490

 548

 606

 627

 624

 623

 611

 601

 620

 591

 609

 628

 610

 651

 640

 597

 605

 609

 617

 534

 363

 287

 273

 276

 297

 342

 381

 406

 440

 476

 510

 573

 618

 637

 642

 641

 629

 623

LOW MEAN

UNITED STATES DEPARTMENT OF THE INTERIOR

U.S. BUREAU OF RECLAMATION-CENTRAL VALLEY PROJECT-CALIFORNIA

SEPTEMBER 2010 WATER QUALITY REPORT RUN DATE: October 15, 2010

ELECTRICAL CONDUCTIVITY, UMHOS 

Comments:

0 reading indicates that the station was out of service.

UNION ISLAND ON OLD RIVER AT MIDDLE RIVER
§ 1822.17 When are documents considered filed simultaneously? ( a ) BLM considers two or more documents simultaneously filed when: ( 1 ) They are received at the appropriate BLM office on the same day and time; or
( 2 ) They are filed in conjunction with an order that specifies that documents received by the appropriate office during a specified period of time will be considered as simultaneously filed.
( b ) An application or document that arrives at the BLM office where it is to be filed when the office is closed for the entire day will be considered as filed on the day and hour the office next officially opens.
( c ) Nothing in this provision will deny any preference right granted by applicable law or regulation or validate a document which is invalid under applicable law or regulation.
#### Robert Holmes, Individually and as Trustee, etc., and Others, Appellants, v. Saint Joseph Lead Company, a Corporation, and Others, Impleaded with Alexander M. White and Others, Doing Business as a Copartnership, etc., Respondents.

Judgment and order affirmed, with costs, on opinions of Cardozo, J., at Special Term. (Reported in 84 Misc. Rep. 278.) Present — Ingraham, P. J., McLaughlin, Clarke, Scott and Dowling, JJ.
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsCreating a Canonical Scientific and Technical Information Classification System for NCSTRL+The purpose of this paper is to describe the new subject classification system for the NCSTRL+ project. NCSTRL+ is a canonical digital library (DL) based on the Networked Computer Science Technical Report Library (NCSTRL). The current NCSTRL+ classification system uses the NASA Scientific and Technical (STI) subject classifications, which has a bias towards the aerospace, aeronautics, and engineering disciplines. Examination of other scientific and technical information classification systems showed similar discipline-centric weaknesses. Traditional, library-oriented classification systems represented all disciplines, but were too generalized to serve the needs of a scientific and technically oriented digital library. Lack of a suitable existing classification system led to the creation of a lightweight, balanced, general classification system that allows the mapping of more specialized classification schemes into the new framework. We have developed the following classification system to give equal weight to all STI disciplines, while being compact and lightweight.Document ID19990005546Acquisition SourceLangley Research CenterDocument TypeTechnical Memorandum (TM)AuthorsTiffany, Melissa E.*(Computer Sciences Corp. Hampton, VA United States)*Nelson, Michael L.*(NASA Langley Research Center Hampton, VA United States)*Date AcquiredSeptember 6, 2013Publication DateDecember 1, 1998Subject CategoryDocumentation And Information ScienceReport/Patent NumberNAS 1.15:208955L-17797NASA/TM-1998-208955Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType19990005546.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
§ 2569.501 What will the BLM do with my application after it is received? After your application is deemed received in accordance with § 2569.411, the BLM will take the following steps: ( a ) The BLM will enter your selection onto the Master Title Plat (MTP) to make the public aware that the land has been segregated from the public land laws.
( b ) The BLM will then determine whether the selection includes only available Federal lands or if the selection conflicts with any other applicant's selection. The BLM will also review its records and aerial imagery to identify, to the extent it can, any valid existing rights that exist within the selection.
( c ) The BLM may make minor adjustments to the shape and description of your selection to match existing property boundaries, roads, or meanderable waterbodies, or to reduce the number of corners or curved boundary segments. The BLM will attempt to retain the acreage requested in the selection, but the adjustment may cause a reduction or addition in the acreage (not to exceed 160 acres).
( d ) After any adjustments have been made, the BLM will send you a Notice of Survey to inform you of the shape and location of the lands the BLM plans to survey. The Notice of Survey will include: ( 1 ) Your original land description;
( 2 ) The adjusted land description plotted onto a Topographic Map and a MTP;
( 3 ) Imagery of your original land description with the adjusted land description projected onto it;
( 4 ) a Draft Plan of Survey; and
( 5 ) A list of valid existing rights that the BLM has identified within the selection.
( e ) The Notice of Survey will provide you an opportunity to challenge, in writing, the Draft Plan of Survey of the adjusted land description within 60 days of receipt of the BLM's notice. If no challenge is received within 60 days, the BLM will deem the Draft Plan of Survey to have been accepted.
( f ) The BLM will finalize the Plan of Survey based on the Draft Plan of Survey in the Notice of Survey or the adjustment you provide pursuant to paragraph (e) of this section.
( g ) The BLM will survey the selection based on the Plan of Survey.
( h ) After survey, the BLM will mail you a document titled Conformance to Plat of Survey. That document will: ( 1 ) Show the selection as actually surveyed;
( 2 ) Plot the survey onto imagery; and
( 3 ) If you found an error in the way the BLM surveyed the selection based on the Plan of Survey, provide an opportunity to dispute the survey in writing within 60 days of receipt of the Conformance of Plat of Survey. If no notice of dispute is received within 60 days, the BLM will deem the survey to have been accepted.
( i ) The BLM will issue a Certificate of Allotment. No right or title of any sort will vest in the selection until the Certificate of Allotment is issued.
( j ) If an application is rejected for any reason, the BLM will remove the corresponding selection from the MTP to make the public aware that the land is no longer segregated from the public land laws.
```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 4519 Introduced in Senate (IS)]

<DOC>

117th CONGRESS
  2d Session
                                S. 4519

   To prohibit the Federal Government from promoting, supporting, or 
 contracting with abortion entities, or otherwise expanding access to 
          abortions on Federal lands or in Federal facilities.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             July 13, 2022

 Mr. Rubio (for himself, Mr. Marshall, Mr. Risch, Mrs. Hyde-Smith, Mr. 
 Wicker, Mr. Daines, Mr. Thune, Mr. Hawley, and Mr. Crapo) introduced 
the following bill; which was read twice and referred to the Committee 
               on Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
   To prohibit the Federal Government from promoting, supporting, or 
 contracting with abortion entities, or otherwise expanding access to 
          abortions on Federal lands or in Federal facilities.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Prohibiting Abortion on Federal 
Lands Act''.

SEC. 2. PROHIBITION ON FEDERAL GOVERNMENT PROMOTION OF ABORTIONS.

    (a) In General.--The Federal Government shall not promote, support, 
or enter into contracts with abortion entities, or otherwise expand 
access to abortions on Federal lands or in Federal facilities, 
including military installations, national parks, court houses, and 
other Federal buildings.
    (b) Definitions.--In this section:
            (1) Abortion.--The term ``abortion'' means the use or 
        prescription of any instrument, medicine, drug, or other 
        substance or device to intentionally kill the unborn child of a 
        women known to be pregnant, or prematurely terminate the 
        pregnancy of a woman known to be pregnant, with an intention 
        other than to increase the probability of a live birth or of 
        preserving the life or health of the child after live birth, or 
        remove a dead unborn child.
            (2) Abortion entity.--The term ``abortion entity'' means an 
        entity, including its affiliates, subsidiaries, successors, and 
        clinics, that performs, induces, refers for, or counsels in 
        favor of abortions, or provides financial support to any other 
        organization that conducts such activities on Federal lands or 
        in Federal facilities.
                                 <all>
```
Exhibit
10.14


 


First
Amendment to Employment Agreement


 


WHEREAS,
MYMD Pharmaceuticals. Inc (the “Company”) and Chris Chapman, MD (“Employee”) (collectively “the Parties”)
entered into an Employment Agreement dated November 1, 2020 (“Agreement”); and


 


WHEREAS,
for good and valuable consideration the Parties hereby amend the Agreement as follows:


 


Section
2 is replaced with the following Section 2 and new Section 3.1 is added as appears below.


 


	2.
    	Term
    of Employment. This Employment Agreement shall commence on the Effective Date and shall continue for a period of two years (the
    “Term of Employment”) unless earlier terminated by either party, which termination shall be effective upon written Notice
    to the other party. In the event of a Notice of Termination issued by the Company for cause, the Employee shall be paid his normal
    monthly Base Salary for three months paid following Notice of Termination which shall constitute Employee’s full and complete
    entitlement to severance compensation.
	 	 
	3.1.	Benefits.
    The Company will provide and cover the cost of health insurance and disability policies for Employee during the Term of Employment.


 


	 	MYMD
    Pharmaceuticals, Inc.
	 	 

    /s/
    James A. McNulty

	 	By:
    James A. McNulty, CEO
	 	 
	 	Date:
    12/18/20
	 	 
	 	/s/
    Chris Chapman, M.D.
	 	Chris
    Chapman, MD


 


	 	Date:
December 18, 2020


 




    	1
EXHIBIT 31.2
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, William M. Scharninghausen, Chief Financial Officer of Vialta, Inc., certify that:
1. I have reviewed this annual report on Form 10-K/A of Vialta, Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report;   Date:May 2, 2005 /s/ William M. Scharninghausen   William M. Scharninghausen Chief Financial Officer